Developmental and epileptic encephalopathies (DEEs) are characterized by pharmaco-resistant seizures with concomitant intellectual disability. Epilepsy of infancy with migrating focal seizures (EIMFS) is one of the most severe of these syndromes. De novo variants in ion channels, including gain-of-function variants in KCNT1 , which encodes for sodium activated potassium channel protein K Na 1.1, have been found to play a major role in the etiology of EIMFS. Here, we test a potential precision therapeutic approach in KCNT1 -associated DEE using a gene-silencing antisense oligonucleotide (ASO) approach. We generated a mouse model carrying the KCNT1 p.P924L pathogenic variant; only the homozygous animals presented with the frequent, debilitating seizures and developmental compromise that are seen in patients. After a single intracerebroventricular bolus injection of a Kcnt1 gapmer ASO in symptomatic mice at postnatal day 40, seizure frequency was significantly reduced, behavioral abnormalities improved, and overall survival was extended compared with mice treated with a control ASO (nonhybridizing sequence). ASO administration at neonatal age was also well tolerated and effective in controlling seizures and extending the life span of treated animals. The data presented here provide proof of concept for ASO-based gene silencing as a promising therapeutic approach in KCNT1 -associated epilepsies.
The TRAPP (TRAnsport Protein Particle) protein complex is a multi-subunit complex involved in vesicular transport between intracellular compartments. The TRAPP complex plays an important role in endoplasmic reticulum-to-Golgi and Golgi-to-plasma membrane transport, as well as autophagy. TRAPP complexes comprise a core complex, TRAPPI, and the association of peripheral protein subunits to make two complexes, known as TRAPPII and TRAPPIII, which act as Guanine Nucleotide Exchange Factors (GEFs) of Rab11 and Rab1, respectively. Rab1 and Rab11 are GTPases that mediate cargo selection, packaging, and delivery during pre- and post-Golgi transport in the secretory pathway. Rab1 is also required for the first step of macroautophagy, a cellular recycling pathway. Pathogenic variants in genes encoding protein subunits of the TRAPP complex are associated with a range of rare but severe neurological, skeletal, and muscular disorders, collectively called TRAPPopathies. Disease-causing variants have been identified in multiple subunits of the TRAPP complex; however, little is known about the underlying disease mechanisms. In this review, we will provide an overview of the current knowledge surrounding disease-associated variants of the TRAPP complex subunits, propose new insights into the underlying disease pathology, and suggest future research directions into the underlying disease mechanisms.
Objective: Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable of generating precisely controlled after‐discharges (ADs) through electrical stimulation. We optimized stimulation parameters to evoke epileptiform‐like hypersynchronous events and validated the model using six approved antiseizure medications (ASMs). Methods: hiPSCs were rapidly differentiated into NGN2 cortical neurons and co‐cultured with astrocytes on a 12‐electrode, 24‐well MEA. Network activity was tracked weekly. Upon maturation, biphasic voltage stimuli (400–2000 mV, 10 pulses at 100 Hz, 100 μs phase width) were applied in 100 ms trains to induce ADs. Stimulation intensity was increased until a maximum spike count per burst was reached. The timing of the stimulating inter‐burst interval (IBI) was shortened from 10 to 1 s. We tested six ASMs with distinct mechanisms of action for their ability to attenuate induced ADs, as measured by the area under the curve (AUC) of spikes within bursts. Results: A ±1000 mV stimulus was sufficient to evoke robust ADs; higher voltages caused network instability without enhancing response strength. The maximum hypersynchronous bursting rate was observed with 2 s IBIs, whereas attempts to induce more frequent events using 1 s IBIs led to desynchronization and a reduction in burst frequency below baseline. Phenytoin, perampanel, clonazepam, and lamotrigine significantly reduced AUC within 5 min in a concentration‐dependent manner. Vigabatrin and levetiracetam required longer pre‐incubations: AUC was reduced after 6 h for levetiracetam and at 24 h for vigabatrin. Significance: We present a novel hiPSC‐derived, electrically induced in vitro model for screening ASM candidates. This approach captures human‐relevant epileptiform dynamics, allows fine control over stimulation parameters, and enables testing of diverse drug mechanisms. Its compatibility with high‐throughput platforms makes it a promising tool for ASM discovery and personalized treatment strategies.
The neuronal progenitor NG108-15 neuroblastoma x glioma cell line proliferates indefinitely in vitro and is capable of directed differentiation into cholinergic neurons. The cell line is a robust model for investigating neuronal differentiation and function in vitro. The lineage-specific transcription factor-mediated differentiation of pluripotent stem cell lines (PSCs) leads to more rapid, efficient, and functional neurons. In this study, we tested the hypothesis that transcription factors could also drive the fate of an immortalised cell line. We first established a stable NG108-15 cell line, by piggyBac (pBac) transposition, that conditionally expresses neurogenin-2 (Ngn2), a common transcription factor for specifying neuronal fate. Following doxycycline-induction of Ngn2, we observed more rapid and efficient differentiation, and improved neurite outgrowth and viability compared with the WT cell line. Moreover, when co-cultured with C2C12 mouse myotubes, the modified NG108-15 cells resulted in significantly larger acetylcholine receptor (AChR) aggregates, suggesting enhanced neuromuscular junction (NMJ) formation. These findings describe a novel methodology for differentiating NG108-15 cells more efficiently, to enhance the usefulness of the cell line as a motor neuron model.